Unimark to develop antibiotic API
The biocatalysis technology is a greener, cleaner, and more economic way to manufacture chiral drugs cutting the production costs by 25-30%. The company has wound up the plans
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.
The open-label dose-escalating trial evaluated toxicity and efficacy of perifosine, given in monotherapy to patients with neuroblastoma. Aeterna Zentaris president and CEO Juergen Engel said the data emphasise
The patent applications concern its proprietary formulation technologies for its products TX12001HR, TX12002HR and TX12003HR. TherapeuticsMD CEO Robert Finizio said, "The submission of these patents marks a new